Quantcast

BioNTech, Fosun Pharma, Phizer working on COVID-19 vaccine. Clinical testing in Germany in April

BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.

Read more

Hutschison China MediTech get’s priority review status for its anti-cancer drug surufatinib

Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).

Read more

ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.

Read more